Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Allergies · Early Parkinson Disease

Advanced Accelerator Applications

Advanced Accelerator Applications patent portfolio — 25 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
20 rue Diesel, Saint Genis Pouilly, 01630, FR, RUEIL-MALMAISON HQ
590 Employees
EMA registrant Type
Company details
Status
Public
HQ
20 rue Diesel, Saint Genis Pouilly, 01630, FR, RUEIL-MALMAISON
Employees
590
Programs
12
Drugs
25
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Advanced Accelerator Applications patents

25 pharmaceutical patents indexed for Advanced Accelerator Applications. 0 expire within 24 months.

Advanced Accelerator Applications has 25 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

25 patents

Patent portfolio

  1. EP 4541380

    STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN

    Expires Tue Apr 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. CA 3235923

    PROCEDES DE SYNTHESE A GRANDE ECHELLE DE COMPLEXES DE RADIONUCLEIDES

    Expires Wed Aug 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. CA 3240096

    POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON

    Expires Thu May 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. CA 3234495

    POLYTHERAPIE DE COMPLEXE DE RADIONUCLEIDES

    Expires Wed Apr 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. CA 3215723

    PROCEDES DE DIAGNOSTIC DU CANCER DE LA PROSTATE

    Expires Wed Oct 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. CA 3202908

    ANTAGONISTE D'INTEGRINES ALPHA-V BETA-3 ET/OU ALPHA-V BETA-5 RADIOMARQUE DESTINE A ETRE UTILISE EN TANT QU'AGENT THERAGNOSTIQUE

    Expires Wed Jun 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 2022072166

    METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS

    Expires Wed Mar 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. WO 2022043557

    MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA

    Expires Wed Feb 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2022043558

    MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA

    Expires Wed Feb 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. AR 120033

    ANTAGONISTA RADIOMARCADO DE GRPR PARA USO COMO AGENTE TERAGNÓSTICO

    Expires Tue Jan 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. AR 119975

    MÉTODOS PARA RADIOMARCAR ANTAGONISTAS DE GRPR Y SUS KITS

    Expires Tue Jan 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. WO 2021219720

    PROCÉDÉS DE RADIOMARQUAGE DE LIGANDS DE LIAISON PSMA ET LEURS KITS

    Expires Wed Oct 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2021219719

    PROCÉDÉS DE RADIOMARQUAGE DE LIGANDS SE LIANT AU PSMA ET LEURS KITS

    Expires Wed Oct 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. WO 2021058549

    ANTAGONISTE GRPR RADIOMARQUÉ POUR L'UTILISATION COMME AGENT THÉRAGNOSTIQUE

    Expires Wed Mar 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. WO 2021052960

    COMPOSITION RADIOPHARMACEUTIQUE CONCENTRÉE, STABLE

    Expires Wed Mar 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. WO 2021053040

    MÉTHODES DE RADIOMARQUAGE D'ANTAGONISTES DE GRPR ET LEURS KITS

    Expires Wed Mar 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. CA 3144557

    LIGANDS D'ANTIGENE MEMBRANAIRE SPECIFIQUE DE LA PROSTATE (PSMA) ET LEURS UTILISATIONS

    Expires Wed Jan 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. WO 2021001362

    LIGANDS D'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE (PSMA) ET LEURS UTILISATIONS

    Expires Wed Jan 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. WO 2020249818

    PROCÉDÉ DE TRAITEMENT DU CANCER PAR DÉPÔT INTRATUMORAL DE MICROPARTICULES RADIOACTIVES

    Expires Wed Dec 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 2020353106

    Stable, concentrated radionuclide complex solutions

    Expires Wed Nov 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 2020131224

    Methods for Synthesis of Radionuclide Complex

    Expires Wed Apr 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. CA 3112060

    COMPOSITION PHARMACEUTIQUE COMPRENANT UN ANTAGONISTE DE GPRP RADIOMARQUE ET UN TENSIOACTIF

    Expires Wed Apr 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. WO 2020064693

    POLYTHÉRAPIE

    Expires Wed Mar 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 2020030466

    Stable, concentrated radionuclide complex solutions

    Expires Wed Jan 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 2020030465

    Stable, concentrated radionuclide complex solutions

    Expires Wed Jan 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Advanced Accelerator Applications have?

25 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Advanced Accelerator Applications patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.